Abstract
Background & Objective: Protein misfolding and aggregation have been considered the common pathological hallmarks for a number of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). These abnormal proteins aggregates damage mitochondria and induce oxidative stress, resulting in neuronal cell death. Prolonged neuronal damage activates microglia and astrocytes, development of inflammation reaction and further promotes neurodegeneration. Thus, elimination of abnormal protein aggregates without eliciting any adverse effects are the main treatment strategies. To overcome this, recent studies have deployed single- chain fragment variable antibodies (scFvs) to target the pathological protein aggregates, such as amyloid-beta (Aβ) peptides, α-synuclein (α-syn) and Huntingtin (Htt). To date scFv has been effective at inhibiting abnormal protein aggregates formation in both in vitro and in vivo model system of AD, PD and HD.
Conclusion: Currently active research is still ongoing to improve the scFv gene delivery technology, to further enhance brain penetration, intracellular stability, solubility and efficacy of scFv intrabody.
Keywords: Inflammation reaction, neurodegenerative disease, oxidative stress, single-chain Fv antibodies, pathological, Alzheimer's disease.
CNS & Neurological Disorders - Drug Targets
Title:Single-chain Fv Antibodies for Targeting Neurodegenerative Diseases
Volume: 17 Issue: 9
Author(s): Kin Yen Chia, Khuen Yen Ng, Rhun Yian Koh and Soi Moi Chye*
Affiliation:
- Applied Biomedical Science and Biotechnology, International Medical University, Kuala Lumpur,Malaysia
Keywords: Inflammation reaction, neurodegenerative disease, oxidative stress, single-chain Fv antibodies, pathological, Alzheimer's disease.
Abstract: Background & Objective: Protein misfolding and aggregation have been considered the common pathological hallmarks for a number of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). These abnormal proteins aggregates damage mitochondria and induce oxidative stress, resulting in neuronal cell death. Prolonged neuronal damage activates microglia and astrocytes, development of inflammation reaction and further promotes neurodegeneration. Thus, elimination of abnormal protein aggregates without eliciting any adverse effects are the main treatment strategies. To overcome this, recent studies have deployed single- chain fragment variable antibodies (scFvs) to target the pathological protein aggregates, such as amyloid-beta (Aβ) peptides, α-synuclein (α-syn) and Huntingtin (Htt). To date scFv has been effective at inhibiting abnormal protein aggregates formation in both in vitro and in vivo model system of AD, PD and HD.
Conclusion: Currently active research is still ongoing to improve the scFv gene delivery technology, to further enhance brain penetration, intracellular stability, solubility and efficacy of scFv intrabody.
Export Options
About this article
Cite this article as:
Chia Yen Kin, Ng Yen Khuen , Koh Yian Rhun and Chye Moi Soi*, Single-chain Fv Antibodies for Targeting Neurodegenerative Diseases, CNS & Neurological Disorders - Drug Targets 2018; 17 (9) . https://dx.doi.org/10.2174/1871527317666180315161626
DOI https://dx.doi.org/10.2174/1871527317666180315161626 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Editorial (Thematic Issue: Playing Well with Others! Initiating and Sustaining Successful Collaborations between Industry, Academia and Government)
Current Topics in Medicinal Chemistry Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design The Ambivalent Role of Apoptosis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Pharmaceutical Design Conformations and Biological Activities of Amyloid Beta Peptide 25-35
Current Protein & Peptide Science Single Chemical Entity Legal Highs: Assessing the Risk for Long Term Harm
Current Drug Abuse Reviews Synthesis and Biological Evaluation of Novel 6-Deoxy-β -D-Psicofuranosyl Mercaptoheterocyclic Compounds
Letters in Drug Design & Discovery Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements
Current Pharmaceutical Design The Transport Mechanism of Extracellular Vesicles at the Blood-Brain Barrier
Current Pharmaceutical Design Pharmacology of Cell Adhesion Molecules of the Nervous System
Current Neuropharmacology Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
Current Pharmaceutical Design Is Elevated Norepinephrine an Etiological Factor in Some Cases of Alzheimers Disease?
Current Alzheimer Research Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Delta Opioid Peptides Derived from Plant Proteins
Current Pharmaceutical Design Brain Magnetic Stimulation in Animal Models: A Valuable Lesson for Clinical Applications
CNS & Neurological Disorders - Drug Targets Interplay Between Cholesterol and Homocysteine in the Exacerbation of Amyloid-β Toxicity in Human Neuroblastoma Cells
CNS & Neurological Disorders - Drug Targets Pharmacokinetics of Ceftriaxone in Carbontetrachloride-Induced Hepatopathic and Uranyl nitrate-Induced Nephropathic Goats Following Single Dose Intravenous Administration
Drug Metabolism Letters Editorial [ HPA Axis Guest Editor: Brian Dyck ]
Current Topics in Medicinal Chemistry Salvinorin A and Related Compounds as Therapeutic Drugs for Psychostimulant-Related Disorders
Current Drug Abuse Reviews Exploring the Anti-Neuroinflammatory Potential of Steroid and Terpenoid-Derived Phytochemicals to Combat Alzheimer's Disease
Current Pharmaceutical Design